Please fill out the form below to contact one of the defective drug lawyers at our practice. We serve clients from Chester County, King of Prussia, and beyond.
The Mayerson Law Offices P.C.
3540 Schuylkill Road Rte 724
Spring City, Pennsylvania 19475
Ph. 610.906.1966
Drug manufacturers have a responsibility to ensure that the drugs they provide for patients are safe. However, sometimes extremely dangerous medications are allowed to slip through the cracks of the drug approval system. Pharmaceutical companies are often financially driven to push their medications onto the market without thorough drug testing. This can result in pain, suffering, and even death for the victims who use these defective drug products. At The Mayerson Law Offices P.C., our defective drug lawyers are dedicated to helping clients from the King of Prussia, Chester County, and Spring City areas seek just compensation for the suffering they endure because of drug company carelessness. Our experience in dealing with Ortho Evra® and Fosamax® defective drug cases has earned us a reputation for outstanding client representation against the most powerful of drug companies.
Ortho Evra® Birth Control Patch
One of the most popular prescribed birth control products in the United States, Ortho Evra® is a transdermal contraceptive patch that is applied to the skin once a week for three weeks at a time. The Ortho Evra® patch is as effective as birth control pills and offers greater convenience.
Recent reports suggest that the Ortho Evra® patch may be a defective drug that can cause life-threatening blood clots to form in the body, which can result in pulmonary embolisms, heart attacks, and stroke.
CBS News reported that the risk for developing blood clots is 14 times higher for women using the Ortho Evra® patch compared to women taking birth control pills. The higher level of estrogen in the patch increases the risk of blood clots developing.
[ back to top ]
In November 2005, Ortho-McNeil Pharmaceutical changed the labeling on the Ortho Evra® patch to include a warning stating that women who use the product will be exposed to higher levels of estrogen than with use of traditional birth control pills. Though Ortho-McNeil did not state that the Ortho Evra® patch is a defective drug, the warning label is a clear indicator that dangers exist.
According to the new warning label, individuals using the patch are exposed to 60 percent more estrogen than those using traditional birth control pills. This increased exposure to estrogen increases the risk of dangerous side effects, such as blood clots.
In September 2006, the Food and Drug Administration (FDA) required Ortho-McNeil to update the label to say that some women who use the product may face a higher chance of developing blood clots.
[ back to top ]
Since its release in April 2002, more than 500 million women have used the Ortho Evra® patch. The failure of Ortho-McNeil, and its parent company, Johnson & Johnson, to acknowledge that the Ortho Evra® patch may be a defective drug and notify the public of the dangerously high levels of estrogen in the product has resulted in more than 16,000 adverse reactions, including 17 blood-clot related deaths, according to the Associated Press.
If you or your loved ones have suffered serious side effects from using the Ortho Evra® patch, you may be entitled to compensation. Contact the defective drug lawyers at The Mayerson Law Offices P.C. in Chester County near King of Prussia for a confidential case evaluation.
[ back to top ]
Fosamax® is a drug widely prescribed for women who are post-menopausal or individuals who have osteoporosis. Manufactured by Merck, the medication is part of a class of drugs called bisphosphonates, which help to increase bone mass and reduce the risk of bone fractures in order to treat and prevent the disease. Bisphosphonate drugs, such as Actonel®, Aredia®, and Boniva®, decrease the rate of bone loss in individuals by reducing the activity of cells that promote bone loss.
However, this process may cause patients suffering from post-menopause and osteoporosis to develop a severe bone disease called osteonecrosis of the jaw (ONJ).
[ back to top ]
Also known as "dead jaw," ONJ occurs when the jaw deteriorates and dies, leading to pain, infection, and exposed bone in the mouth. Individuals with ONJ find that their bone fails to heal after dental trauma. Symptoms include jaw pain, swelling of the gums, numbness in the mouth, loose teeth, and a feeling of heaviness in the jaw.
According to a study published in the Journal of Oral and Maxillofacial Surgeons, 63 patients who were diagnosed with ONJ were receiving bisphosphonate treatment, and 10 percent of those were taking Fosamax®. This suggests Fosamax® may be a defective drug.
In January 2005, the FDA requested that Merck change the labeling on Fosamax® to include the risk for developing jawbone tissue disease after reviewing the safety of Fosamax® and other medications in its class. However, the new label was not added to the product until July 2005. Our defective drug lawyers see this as a delaying tactic by Merck to increase profits at the expense of patients' health.
[ back to top ]
Since Fosamax®, also known as alendronate sodium, hit the market more than 10 years ago, more than 22 million prescriptions have been filled. Many people have filed Fosamax® lawsuits seeking compensation for their pain and suffering, with claims that Merck knowingly withheld information about the dangerous side effects of Fosamax® from the public.
If you or someone you know has taken Fosamax® and experienced symptoms associated with ONJ, contact our defective drug lawyers, serving Spring City, Chester County, Montgomery County, and King of Prussia areas, for a confidential case evaluation.
[ back to top ]
The defective drug lawyers at The Mayerson Law Offices P.C. in Chester County near King of Prussia are dedicated to helping you fight for just compensation if you have been injured through the use of the Ortho Evra® patch, Fosamax®, or any medication. To determine if you have a case, please contact our lawyers today and schedule a private consultation.
[ back to top ]